Darin Leigh Joins Metabolon as Chief Commercial Officer
News Jul 07, 2015
Metabolon, Inc. has announced that Darin Leigh has been appointed Chief Commercial Officer, a new position at the company. He will report to John Ryals, Metabolon’s president and CEO, and oversee commercial strategy for the company’s Metabolomics and Biomarker Services, Precision Medicine, and Diagnostics business units.
"Darin is a proven commercial leader of global organizations and has demonstrated strategic planning and tactical skills that have delivered exceptional results,” said John Ryals, Metabolon CEO. “With more than 23 years’ experience in life science and diagnostic sales, marketing and operations, I have the utmost confidence in his ability to further promote Metabolon’s tremendous technology and advance our business objectives.”
“I joined Metabolon because the ability of its metabolomics technology to impact human health has never been more compelling,” said Leigh. “My team and I have an exciting opportunity to empower health care providers and life science researchers with unprecedented, actionable knowledge. Whether they are working to develop new medicines or healthier foods, or prevent, diagnose and treat disease more quickly and accurately, we have the expertise to support them.”
Prior to joining Metabolon, Leigh was the senior vice president of commercial operations at Asuragen, Inc., a clinical and molecular diagnostics company. He has held senior-level international sales, marketing and operations positions with Luminex Corporation and Abbott Laboratories, where he successfully launched global products and delivered consistent revenue growth. He holds a B.S. in medical laboratory sciences from Paddington College at the University of London.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Synaptic Proteins May Be Starting Point for Dementia TreatmentNews
A new study has identified key proteins, located at the brain's synaptic connections, which may be viable targets for dementia treatment.READ MORE
Comments | 0 ADD COMMENT
Precision Medicine & Biomarkers Leaders Summit: USA
May 07 - May 08, 2018